|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's Range||19.58 - 20.99|
|52 Week Range||15.16 - 27.00|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.33|
Alzheimer's treatment continues to confound biotech companies in the wake of Biogen and Eisai's decision to terminate two late-stage tests. But scientists say there's hope in new theories.
On a per-share basis, the South San Francisco, California-based company said it had a loss of 42 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed ...
In April 2019, Alector dosed the first frontotemporal dementia patient in the Phase 1b portion of the INFRONT clinical study of AL001. In addition to safety, the study will also measure the levels of a critical target specific biomarker, progranulin, in plasma and in cerebrospinal fluid (CSF) to demonstrate proof of mechanism in patients.
SOUTH SAN FRANCISCO, Calif., May 08, 2019 -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Every investor in Alector, Inc. (NASDAQ:ALEC) should be aware of the most powerful shareholder groups...
Alector, Inc. (ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced dosing of the first Alzheimer’s disease patient in the Phase 1b portion of the INVOKE clinical study of AL002. AL002 is a monoclonal antibody that enhances the activity of TREM2 and is being developed by Alector for the treatment of Alzheimer’s disease in collaboration with its partner AbbVie.
Some scientists believe Alzheimer's is a prions-like disease but is not a prions disease as identified by Nobel Prize-winning UCSF researcher Dr. Stanley Prusiner.
This week's Health Care Digest explores growing companies and introduces our new health care reporter, Hannah Norman.
Alector, Inc. (ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced dosing of the first frontotemporal dementia (FTD) patient in the Phase 1b portion of the INFRONT clinical study of AL001 after successful completion of the healthy volunteer single ascending dose escalation portion of the study. “AL001 was generally well tolerated, with no drug-related serious adverse events in healthy volunteers, achieving the study’s primary objective.
The South San Francisco company is putting its IPO where its mouth is — hoping to take its lead drug, targeting a tooth-loss-causing bacteria that migrates from the mouth to the brain, into a Phase II/III clinical trial soon.
China IPO stock and smart e-scooter leader Niu Technologies and biotech IPO Alector just cleared new buy points and joined the IBD Breakout Stocks Index.
The number of Bay Area exits via IPOs and M&A; in the first quarter dropped sharply to 40, according to PitchBook Data, less than half the total from last year's first quarter.
The Sunnyvale-based medical device business sold 6 million shares at $20 each instead of the 4.7 million shares it originally planned to sell for between $15 and $17 apiece.
Alector, Inc. (ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced the initiation of the first-in-human Phase 1 trial for AL003, called the INTERCEPT study. AL003 is the company’s second product candidate being developed for the treatment of patients with Alzheimer’s disease in collaboration with its partner AbbVie. Alector is focused on identifying and functionally repairing genetic mutations that cause dysfunction of the brain immune system leading to neurodegeneration.
- Strong 2018 marked by the company’s first and second programs entering the clinic, targeting frontotemporal dementia and Alzheimer’s disease. Ten programs in Research and.
The life sciences company's shares rose in early trading Thursday by as much 79 percent above its offering price, which was also above its target range.
SOUTH SAN FRANCISCO, Calif., March 06, 2019 -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach.
The amount that the Santa Clara company hopes to raise is about 31 percent above the initial target set when it made its IPO plans public earlier this month.
The downtown San Jose-based video conferencing business could file its public prospectus as early as next month.
The IPO market is expected to show another uptick in volume this week as six initial public offerings are set to price and raise $882.6 million in proceeds. It follows three IPOs last week.
ShockWave has raised about $150 million in funding from investors who include Venrock, T. Rowe Price, Sectoral Asset Management, Sofinnova Capital and Fidelity.
Alector, Inc. (ALEC), a clinical stage biotechnology company, rang the Nasdaq MarketSite bell in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market. Alector is pioneering immuno-neurology, a novel therapeutic approach to counteract the multiple pathologies that cause degenerative brain disorders by restoring healthy immune function to the brain. Supporting its scientific approach, the Company’s Discovery Platform enables them to advance a broad portfolio of product candidates, validated by human genetics, which they believe will improve the probability of technical success of these product candidates and shorten the development timelines to bring these therapies to patients.